LRRK2
Gli inibitori di LRRK2 sono composti che inibiscono l'attività della Leucine-Rich Repeat Kinase 2 (LRRK2), un enzima coinvolto in diversi processi cellulari, tra cui l'autofagia, il traffico vescicolare e l'infiammazione. Le mutazioni nel gene LRRK2 sono associate a un aumento del rischio di sviluppare la malattia di Parkinson, rendendo LRRK2 un bersaglio significativo per la ricerca sulle malattie neurodegenerative. Gli inibitori di LRRK2 sono cruciali per esplorare il ruolo di LRRK2 nel Parkinson e per sviluppare potenziali strategie terapeutiche. Presso CymitQuimica, offriamo una selezione di inibitori di LRRK2 per supportare la tua ricerca in neurodegenerazione, segnalazione chinasi e sviluppo terapeutico.
Trovati 41 prodotti di "LRRK2"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JH-II-127
CAS:JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).Formula:C19H21ClN6O3Purezza:98.32%Colore e forma:SolidPeso molecolare:416.86IKK 16
CAS:IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Formula:C28H29N5OSPurezza:98.76% - 99.61%Colore e forma:SolidPeso molecolare:483.63CZC-25146
CAS:CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Formula:C22H25FN6O4SPurezza:97.68%Colore e forma:SolidPeso molecolare:488.54LRRK2-IN-1
CAS:LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.Formula:C31H38N8O3Purezza:98% - 98.82%Colore e forma:SolidPeso molecolare:570.69PFE-360
CAS:<p>PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase (IC50: 2.3 nM in vivo).</p>Formula:C16H16N6OPurezza:98.14% - 99.73%Colore e forma:SolidPeso molecolare:308.34PF-06371900
CAS:<p>PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).</p>Formula:C17H16N6O2SColore e forma:SolidPeso molecolare:368.41PF-06455943
CAS:PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Formula:C17H14FN5OColore e forma:SolidPeso molecolare:323.32LRRK2-IN-10
CAS:LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Formula:C20H15N5OPurezza:98%Colore e forma:SolidPeso molecolare:341.37LRRK2-IN-7
CAS:LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Formula:C24H26N6OPurezza:99.26%Colore e forma:SolidPeso molecolare:414.5LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Formula:C23H24F2N4O2SColore e forma:SolidPeso molecolare:458.52LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Formula:C24H26F2N4O2SColore e forma:SolidPeso molecolare:472.55SRI-31255
CAS:SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Formula:C15H14N4Colore e forma:SolidPeso molecolare:250.30LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Formula:C18H17ClN8O2Colore e forma:SolidPeso molecolare:412.83LRRK2-IN-4
CAS:LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Formula:C25H29ClF2N6O2Colore e forma:SolidPeso molecolare:518.99LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Formula:C19H19ClN8O2Colore e forma:SolidPeso molecolare:426.86LRRK2-IN-14
CAS:LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Formula:C17H18F3N5O2Colore e forma:SolidPeso molecolare:381.35(R,R)-LRRK2-IN-7
CAS:(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Formula:C24H26N6OPeso molecolare:414.50LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Formula:C24H32ClN7OColore e forma:SolidPeso molecolare:470.01LRRK2-IN-16
CAS:<p>LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.</p>Formula:C18H19N5OSColore e forma:SolidPeso molecolare:353.441LRRK2-IN-2
CAS:LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Formula:C23H23Cl2F3N6O2Colore e forma:SolidPeso molecolare:543.37
